ResearchMoz

Immunoglobulins Market to 2019 - Demand in Primary Immunodeficiency (PI) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) potentially supplemented by approvals for Alzheimers disease

GBI Research
Published Date » 2013-05-03
No. Of Pages » N/A
   
 GBI Research’s report: Immunoglobulin Market to 2019 provides in-depth analysis of the global immunoglobulin market. The report analyzes the markets for immunoglobulin products in the US, the top five European countries (the UK, Germany, France, Italy and Spain) and Japan. The revenue and annual cost of therapy are forecast for the key geographies and in seven key therapeutic segments, along with epidemiology data, until 2019.  
   
 The seven key therapeutic segments are Primary Immunodeficiency (PI), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Multifocal Motor Neuropathy (MMN), Guillain-Barré Syndrome (GBS), Myasthenia Gravis (MG), Idiopathic Thrombocytopenic Purpura (ITP), and Chronic Lymphocytic Leukemia (CLL). The report also profiles the...
Table of Content

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Immunoglobulins Market to 2019 - Introduction
2.1 Overview

3 Immunoglobulins Market to 2019 - Market Overview
3.1 Revenue
3.2 Annual Cost of Therapy
3.3 Immunoglobulins Market Drivers and Restraints
3.3.1 Market Drivers
3.3.2 Restraints

4 Immunoglobulins Market to 2019 - Geographical Landscape
4.1 US
4.1.1 Revenue
4.1.2 Annual Cost of Therapy
4.2 Top Five European Countries
4.2.1 Revenue
4.2.2 Annual Cost of Therapy
4.3 Japan
4.3.1 Revenue
4.3.2 Annual Cost of Therapy

5 Immunoglobulins Market to 2019 - Therapeutic Landscape
5.1 Main Therapeutic Indications
5.1.1 Indicated Conditions for Intravenous Immunoglobulin Usage - US
5.1.2 Indications for Intravenous Immunoglobulin Usage - Europe
5.1.3 Guidelines for Intravenous Immunoglobulin Usage - UK
5.1.4 Indications for Intravenous Immunoglobulin Usage - Japan
5.2 Revenue Share for the Major Therapeutic Indications
5.3 Primary Immunodeficiency Market
5.3.1 Introduction
5.3.2 Revenue
5.3.3 Annual Cost of Therapy
5.3.4 Epidemiology
5.3.5 Current Use
5.3.6 Geographical Segmentation
5.4 Guillain-Barré Syndrome Market
5.4.1 Introduction
5.4.2 Revenue
5.4.3 Annual Cost of Therapy
5.4.4 Epidemiology
5.4.5 Current Use for Therapies
5.4.6 Geographical Segmentation
5.5 Chronic Lymphocytic Leukemia Market
5.5.1 Introduction
5.5.2 Revenue
5.5.3 Annual Cost of Therapy
5.5.4 Epidemiology
5.5.5 Current Use
5.5.6 Geographical Segmentation
5.6 Chronic Inflammatory Demyelinating Polyneuropathy Market
5.6.1 Introduction
5.6.2 Revenue
5.6.3 Annual Cost of Therapy
5.6.4 Epidemiology
5.6.5 Current Use
5.6.6 Geographical Segmentation
5.7 Myasthenia Gravis Market
5.7.1 Introduction
5.7.2 Revenue
5.7.3 Annual Cost of Therapy
5.7.4 Epidemiology
5.7.5 Current Use
5.7.6 Geographical Segmentation
5.8 Multifocal Motor Neuropathy Market
5.8.1 Introduction
5.8.2 Revenue
5.8.3 Annual Cost of Therapy
5.8.4 Epidemiology
5.8.5 Current Use
5.8.6 Geographical Segmentation
5.9 Idiopathic Thrombocytopenic Purpura
5.9.1 Introduction
5.9.2 Revenue
5.9.3 Annual Cost of Therapy
5.9.4 Epidemiology
5.9.5 Current Use
5.9.6 Geographical Segmentation

6 Immunoglobulins Market to 2019 - Profiles of Marketed Products
6.1 Overview
6.2 Privigen
6.2.1 Overview
6.2.2 Approved Indications
6.2.3 Safety
6.2.4 Efficacy
6.3 Gammagard S/D
6.3.1 Overview
6.3.2 Approved Indications
6.3.3 Safety
6.3.4 Efficacy
6.4 Gammagard Liquid
6.4.1 Overview
6.4.2 Approved Indications
6.4.3 Safety
6.4.4 Efficacy
6.5 Octagam 5%
6.5.1 Overview
6.5.2 Approved Indications
6.5.3 Safety
6.5.4 Efficacy
6.6 Flebogamma 10% DIF
6.6.1 Overview
6.6.2 Approved Indications
6.6.3 Safety
6.6.4 Efficacy
6.7 Gamunex-C
6.7.1 Overview
6.7.2 Approved Indications
6.7.3 Safety
6.7.4 Efficacy
6.8 Gammaplex
6.8.1 Overview
6.8.2 Approved Indications
6.8.3 Safety
6.8.4 Efficacy
6.9 HyQvia
6.9.1 Overview
6.9.2 Approved Indications
6.9.3 Safety
6.9.4 Efficacy
6.10 Bivigam
6.10.1 Overview
6.10.2 Approved Indications
6.10.3 Safety
6.10.4 Efficacy

7 Immunoglobulins Market to 2019 - Pipeline Analysis
7.1 Research and Development Pipeline
7.2 Major Pipeline Product Profiles
7.2.1 IVIG3I Grifols 10%
7.2.2 RI-002 (IVIG)

8 Immunoglobulins Market to 2019 - Competitive Landscape
8.1 Baxter International Inc.
8.1.1 Business Description
8.1.2 Recent Developments
8.2 Biotest Pharmaceuticals
8.2.1 Business Description
8.2.2 Recent Developments
8.3 Bio Products Laboratory Ltd.
8.3.1 Business Description
8.3.2 Recent Developments
8.4 CSL Behring Limited
8.4.1 Business Description
8.4.2 Recent Developments
8.5 Grifols S.A.
8.5.1 Business Description
8.5.2 Recent Developments
8.6 Octapharma AG
8.6.1 Business Description
8.6.2 Recent Developments

9 Immunoglobulins Market to 2019 - M&A and Licensing Deals Landscape
9.1 M&A Deals
9.1.1 Grifols Buys 60% of Progenika Biopharma
9.1.2 Grifols Acquires 40% of the Capital of Biotechnology Firm VCN Bioscience
9.1.3 Grifols Purchases Three Plasma Donation Centers in the US from Canada’s Cangene
9.1.4 Baxter Enhances Renal Therapies Portfolio with Acquisition of Gambro
9.2 R&D Licensing Agreements
9.2.1 Baxter and Onconova Announce European Licensing Agreement for Anti-Cancer Compound Rigosertib
9.2.2 Baxter Announces Collaboration with Sanquin to Expand Capacity for Plasma Therapies
9.2.3 Baxter Announces 20 Year Partnership with Hemobras in Brazil

10 Immunoglobulins Market to 2019 - Asia-Pacific and China
10.1 India
10.1.1 Overview
10.1.2 Regulatory Landscape
10.1.3 National Institute for Biologicals
10.1.4 Marketed Products
10.1.5 Product Profiles
10.1.6 Company Profiling
10.2 China
10.2.1 Overview
10.2.2 Regulatory Information
10.2.3 Marketed Products
10.2.4 Company Profiling
10.3 Australia
10.3.1 Overview
10.3.2 Regulatory Landscape
10.3.3 Marketed Products
10.3.4 Product Profiles
10.3.5 Company Profiling

11 Global Immunoglobulins Market: Appendix
11.1 Market Definitions
11.2 Abbreviations
11.3 References
11.4 Research Methodology
11.4.1 Coverage
11.4.2 Secondary Research
11.4.3 Primary Research
11.4.4 Expert Panel Validation
11.5 Contact Us
11.6 Disclaimer

List of Tables


Table 1: Immunoglobulins Market, Top Seven Markets, Revenue ($bn), 2006-2012
Table 2: Immunoglobulins Market, Top Seven Markets, Revenue Forecast ($bn), 2012-2019
Table 3: Immunoglobulins Market, Top Seven Markets, Annual Cost of Therapy ($), 2006-2012
Table 4: Immunoglobulins Market, Top Seven Markets, Annual Cost of Therapy Forecast ($), 2012-2019
Table 5: Immunoglobulins Market, US, Revenue ($bn), 2006-2012
Table 6: Immunoglobulins Market, US, Revenue Forecast ($bn), 2012-2019
Table 7: Immunoglobulins Market, US, Annual Cost of Therapy ($), 2006-2012
Table 8: Immunoglobulins Market, US, Annual Cost of Therapy Forecast ($), 2012-2019
Table 9: Immunoglobulins Market, Top Five European Countries, Revenue ($m), 2006-2012
Table 10: Immunoglobulins Market, Top Five European Countries, Revenue Forecast ($m), 2012-2019
Table 11: Immunoglobulins Market, Top Five European Countries, Annual Cost of Therapy ($), 2006-2012
Table 12: Immunoglobulins Market, Top Five European Countries, Annual Cost of Therapy Forecast ($), 2012-2019
Table 13: Immunoglobulins Market, Japan, Revenue ($m), 2006-2012
Table 14: Immunoglobulins Market, Japan, Revenue Forecast ($m), 2012-2019
Table 15: Immunoglobulins Market, Japan, Annual Cost of Therapy ($), 2006-2012
Table 16: Immunoglobulins Market, Japan, Annual Cost of Therapy Forecast ($), 2012-2019
Table 17: Immunoglobulins Market, US, Approved Indications for IVIG Usage, 2012
Table 18: Immunoglobulins Market, EU, Indicated Conditions for IVIG Usage, 2012
Table 19: Immunoglobulins Market, UK, Guidelines for IVIG Usage, 2012
Table 20: Immunoglobulins Market, Top Seven Markets, PI, Revenue ($bn), 2006-2012
Table 21: Immunoglobulins Market, Top Seven Markets, PI, Revenue Forecast ($bn), 2012-2019
Table 22: Immunoglobulins Market, Top Seven Markets, PI, Annual Cost of Therapy ($), 2006-2012
Table 23: Immunoglobulins Market, Top Seven Markets, PI, Annual Cost of Therapy Forecast ($),
2012-2019
Table 24: Immunoglobulins Market, Top Seven Markets, PI, Epidemiology, 2006-2012
Table 25: Immunoglobulins Market, Top Seven Markets, PI, Epidemiology Forecast, 2012-2019
Table 26: Immunoglobulins Market, Top Seven Markets, PI, Geographical Revenue ($m), 2006-2012
Table 27: Immunoglobulins Market, Top Seven Markets, PI, Geographical Revenue Forecast ($m),
2012-2019
Table 28: Immunoglobulins Market, Top Seven Markets, GBS, Revenue ($m), 2006-2012
Table 29: Immunoglobulins Market, Top Seven Markets, GBS, Revenue Forecast ($m), 2012-2019
Table 30: Immunoglobulins Market, Top Seven Markets, GBS, Annual Cost of Therapy ($), 2006-2012
Table 31: Immunoglobulins Market, Top Seven Markets, GBS, Annual Cost of Therapy Forecast ($),
2012-2019
Table 32: Immunoglobulins Market, Top Seven Markets, GBS, Epidemiology, 2006-2012
Table 33: Immunoglobulins Market, Top Seven Markets, GBS, Epidemiology Forecast, 2012-2019
Table 34: Immunoglobulins Market, Top Seven Markets, GBS, Geographical Revenue ($m), 2006-2012
Table 35: Immunoglobulins Market, Top Seven Markets, GBS, Geographical Revenue Forecast ($m),
2012-2019
Table 36: Immunoglobulins Market, Top Seven Markets, CLL, Revenue ($m), 2006-2012
Table 37: Immunoglobulins Market, Top Seven Markets, CLL, Revenue Forecast ($m), 2012-2019
Table 38: Immunoglobulins Market, Top Seven Markets, CLL, Annual Cost of Therapy ($), 2006-2012
Table 39: Immunoglobulins Market, Top Seven Markets, CLL, Annual Cost of Therapy Forecast ($),
2012-2019
Table 40: Immunoglobulins Market, Top Seven Markets, CLL, Epidemiology, 2006-2012
Table 41: Immunoglobulins Market, Top Seven Markets, CLL, Epidemiology Forecast, 2012-2019
Table 42: Immunoglobulins Market, Top Seven Markets, CLL, Geographical Revenue ($m), 2006-2012
Table 43: Immunoglobulins Market, Top Seven Markets, CLL, Geographical Revenue Forecast ($m),
2012-2019
Table 44: Immunoglobulins Market, Top Seven Markets, CIDP, Revenue ($m), 2006-2012
Table 45: Immunoglobulins Market, Top Seven Markets, CIDP, Revenue Forecast ($m), 2012-2019
Table 46: Immunoglobulins Market, Top Seven Markets, CIDP, Annual Cost of Therapy ($), 2006-2012
Table 47: Immunoglobulins Market, Top Seven Markets, CIDP, Annual Cost of Therapy Forecast ($),
2012-2019
Table 48: Immunoglobulins Market, Top Seven Markets, CIDP, Epidemiology, 2006-2012
Table 49: Immunoglobulins Market, Top Seven Markets, CIDP, Epidemiology Forecast, 2012-2019
Table 50: Immunoglobulins Market, Top Seven Markets, CIDP, Geographical Revenue ($m), 2006-2012
Table 51: Immunoglobulins Market, Top Seven Markets, CIDP, Geographical Revenue Forecast ($m),
2012-2019
Table 52: Immunoglobulins Market, Top Seven Markets, MG, Revenue ($m), 2006-2012
Table 53: Immunoglobulins Market, Top Seven Markets, MG, Revenue Forecast ($m), 2012-2019
Table 54: Immunoglobulins Market, Top Seven Markets, MG, Annual Cost of Therapy ($), 2006-2012
Table 55: Immunoglobulins Market, Top Seven Markets, MG, Annual Cost of Therapy Forecast ($),
2012-2019
Table 56: Immunoglobulins Market, Top Seven Markets, MG, Epidemiology, 2006-2012
Table 57: Immunoglobulins Market, Top Seven Markets, MG, Epidemiology Forecast, 2012-2019
Table 58: Immunoglobulins Market, Top Seven Markets, MG, Geographical Revenue ($m), 2006-2012
Table 59: Immunoglobulins Market, Top Seven Markets, MG, Geographical Revenue Forecast ($m),
2012-2019
Table 60: Immunoglobulins Market, Top Seven Markets, MMN, Revenue ($m), 2006-2012
Table 61: Immunoglobulins Market, Top Seven Markets, MMN, Revenue Forecast ($m), 2012-2019
Table 62: Immunoglobulins Market, Top Seven Markets, MMN, Annual Cost of Therapy ($), 2006-2012
Table 63: Immunoglobulins Market, Top Seven Markets, MMN, Annual Cost of Therapy Forecast ($),
2012-2019
Table 64: Immunoglobulins Market, Top Seven Markets, MMN, Epidemiology, 2006-2012
Table 65: Immunoglobulins Market, Top Seven Markets, MMN, Epidemiology Forecast, 2012-2019
Table 66: Immunoglobulins Market, Top Seven Markets, MMN, Geographical Revenue ($m), 2006-2012
Table 67: Immunoglobulins Market, Top Seven Markets, MMN, Geographical Revenue Forecast ($m), 2012-2019
Table 68: Immunoglobulins Market, Top Seven Markets, ITP, Revenue ($m), 2006-2012
Table 69: Immunoglobulins Market, Top Seven Markets, ITP, Revenue Forecast ($m), 2012-2019
Table 70: Immunoglobulins Market, Top Seven Markets, ITP, Annual Cost of Therapy ($), 2006-2012
Table 71: Immunoglobulins Market, Top Seven Markets, ITP, Annual of Cost Therapy Forecast ($),
2012-2019
Table 72: Immunoglobulins Market, Top Seven Markets, ITP, Epidemiology, 2006-2012
Table 73: Immunoglobulins Market, Top Seven Markets, ITP, Epidemiology Forecast, 2012-2019
Table 74: Immunoglobulins Market, Top Seven Markets, ITP, Geographical Revenue ($m), 2006-2012
Table 75: Immunoglobulins Market, Top Seven Markets, ITP, Geographical Revenue Forecast ($m),
2012-2019
Table 76: Immunoglobulins Market, US, FDA-Approved IVIG Products by Therapeutic Indication,
1994-2013
Table 77: Immunoglobulins Market, Top Five European Countries, EMA-Approved IVIG Products by Therapeutic Indication, 2004-2013
Table 78: Immunoglobulins Market, Global, Phase III Pipeline Molecules, 2013
Table 79: Immunoglobulins Market, Global, Alzheimer’s Disease, Pipeline Molecules, 2013
Table 80: Immunoglobulins Market, Grifols, Global, Marketed Immunoglobulin Products, 2013
Table 81: Immunoglobulins Market, India, PI, Marketed Products, 2013
Table 82: Immunoglobulins Market, India, GBS, Marketed Products, 2013
Table 83: Immunoglobulins Market, India, CLL, Marketed Products, 2013
Table 84: Immunoglobulins Market, India, CIDP, Marketed Products, 2013
Table 85: Immunoglobulins Market, India, ITP, Marketed Products, 2013
Table 86: Immunoglobulins Market, India, Reliance Life Sciences, Key Pipeline Products, 2012-2013
Table 87: Immunoglobulins Market, India, Zydus Cadila, Key Marketed Products, 2012-2013
Table 88: Immunoglobulins Market, India, Sun Pharmaceuticals, Generic Versions of Key Marketed Products, 2012-2013
Table 89: Immunoglobulins Market, China, Blood and Blood Products Industry, 1985-2012
Table 90: Immunoglobulins Market, Australia, IVIG Issued to Patients, by Therapeutic Indication, 2011
Table 91: Immunoglobulins Market, Australia, Marketed Products, CIDP, 2013
Table 92: Immunoglobulins Market, Australia, Marketed Products, CLL, 2013
Table 93: Immunoglobulins Market, Australia, Marketed Products, GBS, 2013
Table 94: Immunoglobulins Market, Australia, Marketed Products, ITP, 2013
Table 95: Immunoglobulins Market, Australia, Marketed Products, PI, 2013

List of Figures


Figure 1: Immunoglobulins Market, Top Seven Markets, Revenue Forecast ($bn), 2006-2019
Figure 2: Immunoglobulins Market, Top Seven Markets, Annual Cost of Therapy Forecast ($), 2006-2019
Figure 3: Immunoglobulins Market, US, Revenue Forecast ($bn), 2006-2019
Figure 4: Immunoglobulins Market, US, Annual Cost of Therapy Forecast ($), 2006-2019
Figure 5: Immunoglobulins Market, Top Five European Countries, Revenue Forecast ($m), 2006-2019
Figure 6: Immunoglobulins Market, Top Five European Countries, Annual Cost of Therapy ($), 2006-2019
Figure 7: Immunoglobulins Market, Japan, Revenue Forecast ($m), 2006-2019
Figure 8: Immunoglobulins Market, Japan, Annual Cost of Therapy ($), 2006-2019
Figure 9: Immunoglobulins Market, Top Seven Markets, Market Share by Therapeutic Indication (%), 2012
Figure 10: Immunoglobulins Market, Top Seven Markets, PI, Revenue Forecast ($bn), 2006-2019
Figure 11: Immunoglobulins Market, Top Seven Markets, PI, Annual Cost of Therapy Forecast ($),
2006-2019
Figure 12: Immunoglobulins Market, Top Seven Markets, PI, Geographical Revenue Forecast ($m),
2006-2019
Figure 13: Immunoglobulins Market, Top Seven Markets, GBS, Revenue Forecast ($m), 2006-2019
Figure 14: Immunoglobulins Market, Top Seven Markets, GBS, Annual Cost of Therapy Forecast ($),
2006-2019
Figure 15: Immunoglobulins Market, Top Seven Markets, GBS, Geographical Revenue Forecast ($m),
2006-2019
Figure 16: Immunoglobulins Market, Top Seven Markets, CLL, Revenue Forecast ($m), 2006-2019
Figure 17: Immunoglobulins Market, Top Seven Markets, CLL, Annual Cost of Therapy Forecast ($),
2006-2019
Figure 18: Immunoglobulins Market, Top Seven Markets, CLL, Geographical Revenue Forecast ($m),
2006-2019
Figure 19: Immunoglobulins Market, Top Seven Markets, CIDP, Revenue Forecast ($m), 2006-2019
Figure 20: Immunoglobulins Market, Top Seven Markets, CIDP, Annual Cost of Therapy Forecast ($),
2006-2019
Figure 21: Immunoglobulins Market, Top Seven Markets, CIDP, Geographical Revenue Forecast ($m),
2006-2019
Figure 22: Immunoglobulins Market, Top Seven Markets, MG, Revenue Forecast ($m), 2006-2019
Figure 23: Immunoglobulins Market, Top Seven Markets, MG, Annual Cost of Therapy Forecast ($),
2006-2019
Figure 24: Immunoglobulins Market, Top Seven Markets, MG, Geographical Revenue Forecast ($m),
2006-2019
Figure 25: Immunoglobulins Market, Top Seven Markets, MMN, Revenue Forecast ($m), 2006-2019
Figure 26: Immunoglobulins Market, Top Seven Markets, MMN, Annual Cost of Therapy Forecast ($),
2006-2019
Figure 27: Immunoglobulins Market, Top Seven Markets, MMN, Geographical Revenue Forecast ($m), 2006-2019
Figure 28: Immunoglobulins Market, Top Seven Markets, ITP, Revenue Forecast ($m), 2006-2019
Figure 29: Immunoglobulins Market, Top Seven Markets, ITP, Annual Cost of Therapy Forecast ($),
2006-2019
Figure 30: Immunoglobulins Market, Top Seven Markets, ITP, Geographical Revenue Forecast ($m),
2006-2019
Figure 31: Immunoglobulins Market, US, FDA-Approved Products by Therapeutic Indication, 2003-2013
Figure 32: Immunoglobulins Market, Australia, IVIG Issued (g/1,000 population), 2006-2012
Figure 33: Immunoglobulins Market, Australia, IVIG Issued to Patients, by Therapeutic Indication, 2011

Upcoming Reports:

Poland: soups and broths market
By - Williams and Marshal Strategy
This report presents a comprehensive overview of the soups and broths market in Poland and its state as of January 2014. It provides detailed analysis of the industry, its dynamics and structure. The purpose of the report is to describe the state of the soups and broths market in Poland, to present actual and retrospective information about the volumes and dynamics of production, imports, exports and consumption, the characteristics of the market for the period 2008-2012 and to build a forecast for the market development until 2018. In the same way, the report presents an elaborate...
Carbon Dioxide (CO2) Monitors Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019
By - Transparency Market Research
Carbon Dioxide (CO2) monitors measures partial pressure or gas concentration with the use of two configurations namely, sidestream and mainstream. Mainstream CO2 monitors measure the respiratory gas directly from airway. Whereas, sidestream devices measure the respiratory gas through nasal or oral cannula. The global carbon dioxide monitors market is witnessing a significant growth owing to increasing requirements in patient monitoring and emerging new application areas. Capnography, recovery rooms, emergency rooms, post anesthesia care units, critical care units and others are various...
Interventional Radiology Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
By - Transparency Market Research
Interventional radiology involves the use of minimally invasive procedures in the diagnosis (example: angiograms) and treatment (example: angioplasties) of various medical conditions. These procedures are performed with the aid of image guidance systems. Interventional radiology includes various processes such as biopsies, cancerous/non-cancerous tumor removal and intravascular procedures. Interventional radiology systems offer best image quality and high efficacy for various diagnostic and treatment procedures.  The Society of Interventional Radiology (SIR) based in the...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

A Health Tech Incubator Started by GE Healthcare
Oct 30, 2014  
For the very first time, a health tech start up campus has been established by GE Healthcare at its headquarters at Helsinki, Finland. This area already has about twenty such healthcare start ups that are working on cloud services, wireless technologies, apps, and sensors that aim at improving healthcare. The main rationale behind such a step is providing opportunities for further...
Net Earnings of DuPont Increases 52% despite Agricultural Turmoil
Oct 29, 2014  
DuPont - The Wilmington, Del-based leading chemical company faced decline of three percent sales to $7.5 billion in the quarter ending of September 30. The company’s third-quarter earnings were increased by 52 percent to $433 million albeit the slow global growth and agricultural downside.   The company witnessed the biggest drags from chemical sales with eight percent...
Appeal for Sanitization in Construction Industry through Government Regulations: CIOB Ghana
Oct 29, 2014  
Rockson Dogbegah - The Chairman of the Chartered Institute of Building Ghana commented that the construction industry needs a thorough cleaning up and assurance of proper growth. Mr. Dogbegah also said that a few factors are extremely important for a proper development in the construction industry. These include keen adherence to standards, supreme sense of professionalism, and sheer pursuance...
Facebook Hints of Rise in Expenses in 2015, Shares Drop
Oct 29, 2014  
Facebook has announced on Tuesday that it is prepping for a dramatic rise in spending in the year 2015. This warning has come combined with a projected slowdown in the company’s revenues after revenues were analyzed at the end of the third quarter of the year. The plans of such hefty spending in the next financial year by the company are indicative of stress in the investor...
China to Invest in UKs Infrastructure Industry
Oct 28, 2014  
As per industry reports, it is expected that in the year 2015, the UK infrastructure will derive benefits from 105 billion pounds of Chinese money. This will involve a host of Chinese machinery suppliers, contractors, and materials producers. The UK government will be spending about half of 225 billion pounds on its own infrastructure. The investors from China will be investing...